Boston Scientific Corp
NYSE:BSX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
54.77
91.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Boston Scientific Corp
Boston Scientific Corp
Selling, General & Administrative
Boston Scientific Corp
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Boston Scientific Corp
NYSE:BSX
|
Selling, General & Administrative
-$5.8B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-7%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Selling, General & Administrative
-$4.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-9%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Selling, General & Administrative
-$1.8B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-8%
|
|
|
Stryker Corp
NYSE:SYK
|
Selling, General & Administrative
-$7.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
|
Abbott Laboratories
NYSE:ABT
|
Selling, General & Administrative
-$11.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Selling, General & Administrative
-$2.1B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-12%
|
|
Boston Scientific Corp
Glance View
Boston Scientific Corp., a global leader in medical devices, has carved out an impressive niche at the intersection of healthcare innovation and patient care. Founded in 1979, the company has since grown into a powerhouse with a diverse portfolio that includes products for cardiology, rhythm management, endoscopy, urology, and more. With a commitment to advancing science and improving lives, Boston Scientific is dedicated to developing cutting-edge technologies that address some of the most pressing challenges in medicine today. This commitment is paired with a strong focus on value creation, making the company's long-term strategy particularly appealing to investors looking for stable growth in the healthcare sector. As a publicly traded company on the New York Stock Exchange under the ticker symbol BSX, Boston Scientific has demonstrated resilience and adaptability, with consistent revenue growth driven by innovation and strategic acquisitions. The company's R&D investments are supported by a robust pipeline of new products and therapies, which promise to enhance therapeutic options and improve patient outcomes. For investors, Boston Scientific represents not just an opportunity to participate in a thriving industry with strong demand fundamentals, but also a chance to align with a firm that embodies the principles of prudent financial management and value creation akin to the teachings of Warren Buffett and Charlie Munger. With a proactive approach to market trends and a commitment to sustainability, Boston Scientific is well-positioned to navigate the evolving healthcare landscape, making it a compelling choice for investors seeking exposure to the lucrative medical devices arena.
See Also
What is Boston Scientific Corp's Selling, General & Administrative?
Selling, General & Administrative
-5.8B
USD
Based on the financial report for Sep 30, 2024, Boston Scientific Corp's Selling, General & Administrative amounts to -5.8B USD.
What is Boston Scientific Corp's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-7%
Over the last year, the Selling, General & Administrative growth was -16%. The average annual Selling, General & Administrative growth rates for Boston Scientific Corp have been -11% over the past three years , -9% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
